priors.science/reviews/sglt2-inhibitors

SGLT2 Inhibitors

The current evidence on 14 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty: how firmly the literature supports the claim as stated.

14claims tracked
222primary papers reviewed
23 Oct 2026latest evidence review
6 Established · 6 Likely · 1 Uncertain · 1 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
SGLT2 inhibitors increase the risk of genital mycotic infectionsEstablished92%20
SGLT2 inhibitors are associated with euglycaemic diabetic ketoacidosisEstablished90%23
SGLT2 inhibitors slow kidney disease progression and reduce kidney failure riskEstablished88%23
SGLT2 inhibitors reduce hospitalisation for heart failure in T2DEstablished88%22
Empagliflozin reduces cardiovascular death in T2D patients with established CVDEstablished85%19
SGLT2 inhibitors reduce CV death and HF hospitalisation in HFrEFEstablished85%20
SGLT2 inhibitors reduce CV death and HF hospitalisation in HFpEFLikely84%20
SGLT2 inhibitor kidney benefit extends to CKD patients without diabetesLikely80%20
Canagliflozin is associated with increased risk of lower limb amputationLong-standingLikely80%16
SGLT2 inhibitors reduce all-cause mortality in HFrEFLikely78%23
SGLT2 inhibitor kidney benefit is greatest in patients with high albuminuriaLikely72%20
SGLT2 inhibitors reduce MACE in T2D with established cardiovascular diseaseLikely71%18
SGLT2 inhibitors do not significantly reduce CV mortality in HFpEFUncertain64%21
SGLT2 inhibitors do not reduce MACE in T2D without established CVDDoubtful32%21
Track SGLT2 Inhibitors.
These claims are re-checked against new research as it is published. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing: what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it. Confidently false as stated.
A standing changes only when the score moves past a boundary by more than 4 points, the re-scoring noise floor; a score within 4 points of a boundary keeps its previous standing.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.